iShares Global Healthcare ETF (IXJ)
92.81
+0.00 (0.00%)
NYSE · Last Trade: Oct 24th, 1:48 AM EDT
Detailed Quote
| Previous Close | 92.81 |
|---|---|
| Open | 92.51 |
| Day's Range | 92.50 - 92.95 |
| 52 Week Range | 80.68 - 96.12 |
| Volume | 122,564 |
| Market Cap | 40.47M |
| Dividend & Yield | 1.526 (1.64%) |
| 1 Month Average Volume | 241,324 |
Chart
News & Press Releases
Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Reportstocktwits.com
Via Stocktwits · October 22, 2025
Trump Walks Back Plan To Slap Tariffs On Generic Drugs After White House Clash Over Prices, Supply Risks: Reportstocktwits.com
Via Stocktwits · October 8, 2025
The Trump administration is investigating Medicaid spending in California and other Democrat-led states over potential misuse in immigrant healthcare programs.
Via Benzinga · September 6, 2025
The Fabrizio Ward survey of 1,000 voters found 77% of Trump supporters back measles shots and 69% support hepatitis B, while at least 90% of Kamala Harris voters backed all three vaccines.
Via Stocktwits · September 3, 2025
CDC In Crisis: Kennedy Pressured To Quit As States Revolt Over Vaccine Board Shake-Upstocktwits.com
Via Stocktwits · September 3, 2025
Trump’s Big Pharma Tariff Call Delayed Again As White House Juggles Trade Battles And Diplomatic Showdowns: Reportstocktwits.com
Via Stocktwits · August 13, 2025
Trump Plans Gradual Tariff Hike On Imported Pharma To 250% Over 18 Months To Boost US Productionstocktwits.com
Via Stocktwits · August 5, 2025
RFK Jr. Said To Be Planning Another Health Panel Shakeup — This Time Targeting Preventive Carestocktwits.com
Via Stocktwits · July 29, 2025
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZenecastocktwits.com
Via Stocktwits · August 5, 2025
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinchstocktwits.com
Via Stocktwits · July 31, 2025
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics.
Via Stocktwits · July 31, 2025
In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at the top echelons of the Danish drugmaker sent shockwaves through the investor community, wiping billions off its market capitalization and
Via MarketMinute · July 29, 2025

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
Via Benzinga · February 24, 2025

The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.
Via Stocktwits · January 31, 2025

During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually.
Via Stocktwits · January 22, 2025

Trump signs an order to withdraw the U.S. from WHO, citing pandemic mismanagement, political influence, and inequitable funding, reigniting a past debate.
Via Benzinga · January 22, 2025

Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.
Via MarketBeat · August 9, 2024

You don't need to be a stock market expert to earn above-average returns.
Via The Motley Fool · June 22, 2024

Top ETFs for all 11 S&P 500 sectors.
Via The Motley Fool · February 22, 2024

The top ETFs for 2024 are thematic or sector-specific tickers with upside, presenting market-beating opportunities.
Via InvestorPlace · January 10, 2024

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via Benzinga · December 29, 2023

Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks.
Via InvestorPlace · December 25, 2023
Rather than holding your cash, consider investing it in these stable ETFs.
Via The Motley Fool · May 25, 2023

Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health crises. The deadline for a decision has been December 17, but there has been an unresolved stand-off on the issue at the WTO.
Via Benzinga · December 6, 2022

With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification.
Via InvestorPlace · May 13, 2022